WASHINGTON--(BUSINESS WIRE)--The following statement was issued today by Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood regarding today’s vote in the U.S. Senate to consider legislation amending the successful Medicare Drug Benefit:
